Food Allergy Advances: Oral Immunotherapy, Peanut Patch (EPIT) Etc.
It is very exciting to see advances in food allergy treatment. Currently the only FDA approved “treatment” includes food allergen avoidance and epinephrine auto-injectors. However, there are new treatments which are on the cusp of FDA approval. For example, epicutaneous immunotherapy (EPIT) using a Viaskin patch is being studied by DBV and Oral Immunotherapy (OIT) is being studied by Aimmune Therapeutics. Both are in Phase III clinical trials and both are planning to present data to the FDA later this year. Additionally exciting is that on 8/13/18 the FDA granted a Breakthrough Designation to omalizumab (Xolair) for the treatment of food allergy. Breakthrough designation is a process designed to expedite the development of drugs that are intended to treat a serious condition where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy. At Coastal Allergy Care we are happy and excited to see these advances come to fruition. Food allergy is a major concern and our board certified allergist’s are committed to providing tested, proven and safe treatments for our patients. Our practice has extensive experience using Xolair for the treatment of asthma and hives and embraces the possibility of using it to treat food allergy too! Between the data from the learning early about peanut allergy (LEAP) study and these new potential treatments for established food allergy we hope to drastically decrease the incidence and prevalence of this problem.
If you have any questions about a new food allergy, an established food allergy update, food challenges, or food allergy treatments give us a call 805-482-8989 and let one of our board certified allergist’s help you navigate.
https://www.mdmag.com/medical-news/omalizumab-granted-breakthrough-designation-for-food-allergies
No Comments